Literature DB >> 28647375

Type-I interferon signalling through IFNAR1 plays a deleterious role in the outcome after stroke.

Moses Zhang1, Catherine E Downes1, Connie H Y Wong2, Kate M Brody1, Pedro L Guio-Agulair1, Jodee Gould3, Robert Ates1, Paul J Hertzog3, Juliet M Taylor1, Peter J Crack4.   

Abstract

Neuroinflammation contributes significantly to the pathophysiology of stroke. Here we test the hypothesis that the type I interferon receptor (IFNAR1) plays a critical role in neural injury after stroke by regulating the resultant pro-inflammatory environment. Wild-type and IFNAR1-/- primary murine neurons and glia were exposed to oxygen glucose deprivation (OGD) and cell viability was assessed. Transient cerebral ischemia/reperfusion injury was induced by mid-cerebral artery occlusion (MCAO) in wild-type and IFNAR1-/- and IFNAR2-/- mice in vivo, and infarct size, and molecular parameters measured. To block IFNAR1 signalling, wild-type mice were treated with a blocking monoclonal antibody directed to IFNAR1 (MAR-1) and MCAO was performed. Quantitative PCR confirmed MCAO in wild-type mice induced a robust type-I interferon gene regulatory signature. Primary cultured IFNAR1-deficient neurons were found to be protected from cell death when exposed to OGD in contrast to primary cultured IFNAR1-deficient glial cells. IFNAR1-/- mice demonstrated a decreased infarct size (24.9 ± 7.1 mm3 n = 8) compared to wild-type controls (65.1 ± 4.8 mm3 n = 8). Western blot and immunohistochemistry showed alterations in Akt and Stat-3 phosphorylation profiles in the IFNAR1-/- brain. MAR-1 injection into WT mice (i.v. 0.5 mg 60 min prior to MCAO) resulted in a 60% decrease in infarct size when compared to the IgG control. IFNAR2-/- mice failed to display the neuroprotective phenotype seen in IFNAR1-/- mice after MCAO. Our data proposes that central nervous system signalling through IFNAR1 is a previously unrecognised factor that is critical to neural injury after stroke.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28647375     DOI: 10.1016/j.neuint.2017.06.009

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  7 in total

Review 1.  The Influence of Mitochondrial-DNA-Driven Inflammation Pathways on Macrophage Polarization: A New Perspective for Targeted Immunometabolic Therapy in Cerebral Ischemia-Reperfusion Injury.

Authors:  Sihang Yu; Jiaying Fu; Jian Wang; Yuanxin Zhao; Buhan Liu; Jiahang Wei; Xiaoyu Yan; Jing Su
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

Review 2.  Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway.

Authors:  Isabelle Meyts; Jean-Laurent Casanova
Journal:  Eur J Immunol       Date:  2021-04-04       Impact factor: 5.532

Review 3.  The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury.

Authors:  Li Ning; Xiong Rui; Wang Bo; Geng Qing
Journal:  Cell Death Dis       Date:  2021-07-23       Impact factor: 8.469

Review 4.  The role of microglia in ischemic preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Glia       Date:  2019-08-06       Impact factor: 8.073

5.  Identifying the pattern of immune related cells and genes in the peripheral blood of ischemic stroke.

Authors:  Zijian Li; Yueran Cui; Juan Feng; Yanxia Guo
Journal:  J Transl Med       Date:  2020-08-03       Impact factor: 5.531

6.  HDAC3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway.

Authors:  Yajin Liao; Jinbo Cheng; Xiangxi Kong; Shuoshuo Li; Xiaoheng Li; Meijuan Zhang; He Zhang; Tianli Yang; Yuan Dong; Jun Li; Yun Xu; Zengqiang Yuan
Journal:  Theranostics       Date:  2020-07-29       Impact factor: 11.556

Review 7.  Neuroinflammatory Triangle Presenting Novel Pharmacological Targets for Ischemic Brain Injury.

Authors:  Zaib A Shaheryar; Mahtab A Khan; Ch Sherjeel Adnan; Awais Ali Zaidi; Daniel Hänggi; Sajjad Muhammad
Journal:  Front Immunol       Date:  2021-10-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.